Literature DB >> 16446167

Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.

Alvaro Lladser1, Mario Párraga, Licarallén Quevedo, Maria Carmen Molina, Soledad Silva, Arturo Ferreira, Rosario Billetta, Andrew F G Quest.   

Abstract

Survivin, a 16.5 kDa tumor associated antigen, is the smallest member of the inhibitor of apoptosis family that is abundantly expressed during development but essentially absent in normal adult tissues. Interestingly, survivin expression is up-regulated in virtually all types of cancers studied, as well as in vascular endothelial cells during tumor associated angiogenesis. Survivin links apoptosis to cell cycle progression and plays a pivotal role in regulation of cell proliferation. These characteristics make survivin a potentially promising generic target for cancer immunotherapy. Hence, a genetic immunization strategy to induce tumor-specific immune responses against human survivin in a pre-clinical animal model was developed. In initial studies, BALB/c mice were immunized by intramuscular injection with DNA coding for human survivin (pcDNA3.1/hSurv). In addition, a construct encoding a secreted version of survivin (pSecTag2B/hSurv) was designed. A plasmid coding for murine granulocyte-macrophage colony-stimulating factor (GM-CSF) was co-injected in both cases as a molecular adjuvant. Expression of survivin following transfection in mouse cells was corroborated. Humoral responses against human survivin were detected in mice sera using two immunization protocols (injections at 2- or 3-week intervals). The humoral response was markedly improved by secretion of survivin and co-expression of GM-CSF. The predominant antibody subclass detected in responsive mice was IgG2a, suggesting that a Th1-CD4+ cellular response had been induced. Furthermore, DNA immunization with survivin encoding vectors generated an effective CD8+ T cell response measured as an increase of cytotoxic Interferon-gamma (IFN-gamma) secreting CD8+ T cells. In conclusion, intramuscular genetic immunization of mice with human survivin encoding plasmids induced a survivin-specific humoral as well as cellular immune response in recipient mice. Secretion of survivin and co-injection of GM-CSF as a genetic adjuvant appear to be more important in generating an humoral than a cellular immune response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16446167     DOI: 10.1016/j.imbio.2005.08.002

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

1.  T-cell responses to survivin in cancer patients undergoing radiation therapy.

Authors:  Dörthe Schaue; Begonya Comin-Anduix; Antoni Ribas; Li Zhang; Lee Goodglick; James W Sayre; Annelies Debucquoy; Karin Haustermans; William H McBride
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

2.  Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription.

Authors:  J C Tapia; V A Torres; D A Rodriguez; L Leyton; A F G Quest
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-27       Impact factor: 11.205

3.  Vaccines targeting the neovasculature of tumors.

Authors:  Agata Matejuk; Qixin Leng; Szu-Ting Chou; Archibald J Mixson
Journal:  Vasc Cell       Date:  2011-03-08

Review 4.  Localization and upregulation of survivin in cancer health disparities: a clinical perspective.

Authors:  Salma Khan; Heather Ferguson Bennit; Malyn May Asuncion Valenzuela; David Turay; Carlos J Diaz Osterman; Ron B Moyron; Grace E Esebanmen; Arjun Ashok; Nathan R Wall
Journal:  Biologics       Date:  2015-07-09

Review 5.  Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?

Authors:  Samuel C Wagner; Thomas E Ichim; Hong Ma; Julia Szymanski; Jesus A Perez; Javier Lopez; Vladimir Bogin; Amit N Patel; Francisco M Marincola; Santosh Kesari
Journal:  J Transl Med       Date:  2015-10-29       Impact factor: 5.531

6.  Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo.

Authors:  Lorena Aguilar-Guzmán; Lorena Lobos-González; Carlos Rosas; Gerardo Vallejos; Cristián Falcón; Eduardo Sosoniuk; Francisca Coddou; Lisette Leyton; David Lemus; Andrew F G Quest; Arturo Ferreira
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.